Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026)
Azitra (AZTR) posted Liabilities and Shareholders Equity of $12.1 million for Q1 2026, up 141.31% on a QoQ basis from $5.0 million in Q4 2025, and up 105.26% year-over-year from $5.9 million in Q1 2025.
Azitra (AZTR) Liabilities and Shareholders Equity (2022 - 2026) Analysis & Trends
Azitra's Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $12.1 million for Q1 2026.
- Quarterly Liabilities and Shareholders Equity rose 105.26% year-over-year to $12.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $25.4 million (down 5.64% YoY) and the FY2025 annual result came in at $5.0 million, down 31.71% from the prior year.
- Liabilities and Shareholders Equity was $12.1 million for Q1 2026 at Azitra, up from $5.0 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $12.1 million in Q1 2026 and bottomed at $3.9 million in Q2 2024.
- A 5-year average of $6.8 million and a median of $6.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity sank 60.5% — and 2026, when it surged 105.26%.
- Azitra's Liabilities and Shareholders Equity stood at $7.2 million in 2022, then fell by 28.63% to $5.1 million in 2023, then surged by 43.85% to $7.4 million in 2024, then tumbled by 31.71% to $5.0 million in 2025, then soared by 141.31% to $12.1 million in 2026.
- Business Quant data shows AZTR's Liabilities and Shareholders Equity at $12.1 million in Q1 2026, $5.0 million in Q4 2025, and $4.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Nanobiotix | 1,792.52 Bn | 1,792.46 Bn | - | 77.11 Mn |
| 2 | Akari Therapeutics | 999.95 Bn | 999.95 Bn | - | 33.89 Mn |
| 3 | BeOne Medicines | 475.97 Bn | 471.17 Bn | 1.35 Bn | 8.55 Bn |
| 4 | Vertex Pharmaceuticals | 124.91 Bn | 117.66 Bn | 2.59 Bn | 26.48 Bn |
| 5 | Regeneron Pharmaceuticals | 72.31 Bn | 63.56 Bn | 3.31 Bn | 40.87 Bn |
| 6 | Belite Bio | 62.01 Bn | 62.01 Bn | - | 811.27 Mn |
| 7 | Argenx Se | 54.23 Bn | 49.04 Bn | 1.41 Bn | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 38.31 Bn | 35.30 Bn | 959.66 Mn | 5.13 Bn |
| 9 | Revolution Medicines | 36.16 Bn | 36.16 Bn | - | 2.25 Bn |
| 10 | Azitra | 2.05 Mn | 2.05 Mn | - | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.13 Mn |
| Dec 31, 2025 | 5.03 Mn |
| Sep 30, 2025 | 4.30 Mn |
| Jun 30, 2025 | 3.96 Mn |
| Mar 31, 2025 | 5.91 Mn |
| Dec 31, 2024 | 7.36 Mn |
| Sep 30, 2024 | 9.78 Mn |
| Jun 30, 2024 | 3.88 Mn |
| Mar 31, 2024 | 6.07 Mn |
| Dec 31, 2023 | 5.12 Mn |
| Sep 30, 2023 | 7.49 Mn |
| Jun 30, 2023 | 9.83 Mn |
| Dec 31, 2022 | 7.17 Mn |